GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GRAIL Inc (MEX:GRAL) » Definitions » Capex-to-Revenue

GRAIL (MEX:GRAL) Capex-to-Revenue : 0.03 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is GRAIL Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

GRAIL's Capital Expenditure for the three months ended in Sep. 2024 was MXN-19.12 Mil. Its Revenue for the three months ended in Sep. 2024 was MXN564.17 Mil.

Hence, GRAIL's Capex-to-Revenue for the three months ended in Sep. 2024 was 0.03.


GRAIL Capex-to-Revenue Historical Data

The historical data trend for GRAIL's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GRAIL Capex-to-Revenue Chart

GRAIL Annual Data
Trend Dec18 Dec19 Dec22 Dec23
Capex-to-Revenue
- - 0.41 0.14

GRAIL Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.13 0.10 0.04 0.03

Competitive Comparison of GRAIL's Capex-to-Revenue

For the Diagnostics & Research subindustry, GRAIL's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GRAIL's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GRAIL's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where GRAIL's Capex-to-Revenue falls into.



GRAIL Capex-to-Revenue Calculation

GRAIL's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-218.747) / 1580.387
=0.14

GRAIL's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-19.119) / 564.166
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GRAIL  (MEX:GRAL) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


GRAIL Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of GRAIL's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


GRAIL Business Description

Comparable Companies
Traded in Other Exchanges
Address
1525 O’Brien Drive, Menlo Park, CA, USA, 94025
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.